274 related articles for article (PubMed ID: 33979951)
1. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
Han C; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
[TBL] [Abstract][Full Text] [Related]
2. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
Han C; Lai PP; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
[TBL] [Abstract][Full Text] [Related]
3. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
4. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
[TBL] [Abstract][Full Text] [Related]
5. Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era.
Nishikawa H; Kim SK; Asai A
In Vivo; 2024; 38(1):40-47. PubMed ID: 38148074
[TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
[TBL] [Abstract][Full Text] [Related]
7. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
Abu-Amara M; Feld JJ
Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
[TBL] [Abstract][Full Text] [Related]
8. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
Chong CC; Wong GL; Lai PB
World J Gastroenterol; 2014 May; 20(20):6006-12. PubMed ID: 24876723
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
10. [Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].
Liu ZH; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):842-845. PubMed ID: 31941239
[TBL] [Abstract][Full Text] [Related]
11. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Triolo M; Della Corte C; Colombo M
Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
[TBL] [Abstract][Full Text] [Related]
12. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
13. Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy.
Wu L; Yang Z; Zheng M
J Viral Hepat; 2024 May; 31(5):255-265. PubMed ID: 38332479
[TBL] [Abstract][Full Text] [Related]
14. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
Liu S; Deng R; Zhou B; Liang X; Liu Z; Peng J; Chen J; Zhou Y; Guo Y; Chen Y; Li W; Shen S; Lu X; Zhao S; Liao X; Liang H; Lan Y; Hou J; Fan R; Sun J
J Infect Dis; 2022 Sep; 226(5):881-890. PubMed ID: 34931674
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
[TBL] [Abstract][Full Text] [Related]
18. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
19. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
20. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
Hall S; Howell J; Visvanathan K; Thompson A
Viruses; 2020 Aug; 12(9):. PubMed ID: 32854335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
